Your session is about to expire
← Back to Search
Immunotherapy + Adoptive Cell Therapy for Melanoma
Study Summary
This trial is testing the safety and benefits of using a patient's own immune cells to fight cancer, in combination with a drug that boosts the immune system.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 3 trial • 1289 Patients • NCT01285609Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have serious heart rhythm problems.My brain scans show no growth in my cancer 90 days after treatment for more than 3 or larger than 1 cm brain tumors.I am taking immunosuppressive drugs for an autoimmune disease.I am unable to understand and agree to the study's details.I do not have any major infections or illnesses that would make treatment too risky.I have not had any cancer other than melanoma in the last 2 years, except for certain treated cancers.I am a man and will use two forms of birth control with my partner who can have children, starting from my first ipilimumab dose and for 6 months after treatment ends.I agree to use two approved birth control methods during and 6 months after treatment.My tumor may have a BRAF mutation, and I haven't been treated with ipilimumab.I have been treated with ipilimumab before.I may or may not have had treatment for my metastatic disease. If I have a V600 BRAF mutation, I might have been treated with a BRAF inhibitor.I have up to 3 untreated brain tumors, with at least one larger than 1 cm or causing swelling.You have certain infectious diseases.My kidney, liver, and blood tests are within normal ranges.I can do all or most of my usual activities.I have had surgery or radiation for brain metastases and meet specific conditions.Women who could become pregnant must have a negative pregnancy test within 7 days of being checked for the study.I have up to 3 untreated brain metastases.I am not on long-term steroids for immune suppression.I tested positive for Epstein-Barr virus antibodies.I have antibiotic allergies, but I understand the treatment minimizes exposure.You have a serious mental health condition that could make it hard to understand the study or make immunotherapy treatment unsafe for you.I have more than 3 untreated brain metastases or swelling around the tumor.I still have visible cancer after surgery aimed at growing immune cells.I have advanced melanoma that cannot be removed by surgery and am considered a good candidate for a specific immune therapy.
- Group 1: Combination Therapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the present population size of this clinical trial?
"At this moment, no further participants are being sought for the trial posted on October 9th 2012 and last amended on November 8th 2022. If you search other clinical trials related to metastatic melanoma there are currently 767 open studies and 1220 involving Ipilimumab recruiting patients."
Are there still opportunities to participate in this experiment?
"Based on the information published on clinicaltrials.gov, this specific medical trial is no longer accepting subjects into their research program as it was last edited in November 2022. Nevertheless, there are 1987 other ongoing studies looking for participants at present time."
Have researchers previously conducted research studies using Ipilimumab?
"As of now, 1220 clinical trials have been launched to investigate the usage of ipilimumab. Of these live studies, 200 are in Phase 3. While Philadelphia is a major hub for this treatment's research, there exists 49 026 trial sites across America offering it."
What medical conditions is Ipilimumab typically employed to assuage?
"Ipilimumab is the preferred treatment for a variety of malignancies, particularly lung cancer. The drug has also been known to help treat multiple sclerosis, leukemia, myelocytic, acute and inoperable melanoma cases."
Share this study with friends
Copy Link
Messenger